Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483467 | 0.89 | JAK2 (0.46) | MRGPRX4NR4A2SRD5A2JAK2JAK1 | |
| SCHEMBL20876895 | 0.86 | NR4A2 (0.51) | NR4A2SRD5A2MAOBFFAR4PTPN1 | |
| SCHEMBL2727830 | 0.86 | NR4A2 (0.51) | NR4A2SRD5A2MAOBFFAR4PTPN1 | |
| SCHEMBL2713179 | 0.86 | NR4A2 (0.51) | NR4A2SRD5A2MAOBFFAR4PTPN1 | |
| SCHEMBL8696040 | 0.78 | CHRNB4 (0.45) | — | |
| SCHEMBL9542642 | 0.77 | RAB9A (0.39) | SMN1; SMN2 | |
| SCHEMBL14328250 | 0.77 | RAB9A (0.39) | SMN1; SMN2 | |
| SCHEMBL22534143 | 0.77 | KCNH2 (0.50) | NR4A2SRD5A2MAOBSMN1; SMN2KCNH2 | |
| SCHEMBL22534142 | 0.77 | KCNH2 (0.50) | NR4A2SRD5A2MAOBSMN1; SMN2KCNH2 | |
| SCHEMBL4556877 | 0.77 | RXRA (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324022-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-7855218-B2 | (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels | Convergence Pharmaceuticals Limited (GB) | 2010-12-21 | — | — | US | disclosed |
| US-7803833-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| EP-1943216-B1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LTD (GB) | 2010-06-30 | — | — | EP | disclosed |
| US-20080306122-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080293753-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-11-27 | — | — | US | disclosed |
| EP-1943216-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| EP-1934176-A1 | QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS | GLAXO GROUP LIMITED (GB) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042240-A1 | QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042250-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324022-A1 | NOVEL COMPOUNDS | CYP46A1, NPC1, CYP11B1 | MRGPRX4 72/4885NR4A2 2130/4885SRD5A2 395/4885 |
| US-20080306122-A1 | Novel Compounds | CYP11B1, CYP11B2, CYP46A1 | MRGPRX4 111/4885NR4A2 3073/4885SRD5A2 366/4885 |
| US-20080293753-A1 | Novel Compounds | CACNA1E, CACNA1A, SCN1B | MRGPRX4 458/4885NR4A2 1963/4885SRD5A2 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.